Literature DB >> 11173624

Immunologic Profile of Patients Suffering from Herpes Simplex Virus (HSV) -Associated Oral Lesions Treated with Natural Human Interferon Alpha (Egiferon).

György Kövesi1, Katalin Pálóczi, Klára Ónody, Béla Fekete.   

Abstract

10 consecutive patients with HSV-associated chronic oral lesions were treated with Egiferon for ten days. There were a statistically significant increase in the Large Granule Lymphocyte (LGL) counts and the number of spontaneous E rosette forming cells by the end of the treatment period. Interferon alpha brought about a preferential expression of CD8, CD11b, CD14, CD25 and CD45RO cell surface molecules without any effect on the expression of CD2, CD3, CD4, CD20 and HLA-DR.

Entities:  

Year:  1997        PMID: 11173624     DOI: 10.1007/bf02893352

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  18 in total

Review 1.  The natural history of recurrent oral-facial herpes simplex virus infection.

Authors:  S L Spruance
Journal:  Semin Dermatol       Date:  1992-09

2.  Monoclonal antibody OPD4 is reactive with CD45RO, but differs from UCHL1 by the absence of monocyte reactivity.

Authors:  S Poppema; R Lai; L Visser
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

3.  Clinical performance of natural human leukocyte interferon.

Authors:  K Cantell
Journal:  Immunobiology       Date:  1986-09       Impact factor: 3.144

4.  alpha-Interferon therapy in patients with chronic active hepatitis B: immunological profile.

Authors:  M Raptopoulou-Gigi; H Orphanou-Koumerkeridou; F Lagra; J Vacolas; G Goulis; H Vrettou
Journal:  J Investig Allergol Clin Immunol       Date:  1991-10       Impact factor: 4.333

5.  Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen.

Authors:  M R Brunetto; F Oliveri; G Rocca; D Criscuolo; E Chiaberge; M Capalbo; E David; G Verme; F Bonino
Journal:  Hepatology       Date:  1989-08       Impact factor: 17.425

6.  Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations.

Authors:  A J Beniers; R J van Moorselaar; W P Peelen; F M Debruyne; J A Schalken
Journal:  Urol Res       Date:  1991

7.  Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection.

Authors:  G J Alexander; J Brahm; E A Fagan; H M Smith; H M Daniels; A L Eddleston; R Williams
Journal:  Lancet       Date:  1987-07-11       Impact factor: 79.321

8.  Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia--a pilot study.

Authors:  M Talpaz; M Rosenblum; R Kurzrock; J Reuben; H Kantarjian; J Gutterman
Journal:  Am J Hematol       Date:  1987-04       Impact factor: 10.047

9.  Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results.

Authors:  K A Foon; A E Maluish; P G Abrams; S Wrightington; H C Stevenson; A Alarif; M F Fer; W R Overton; M Poole; E F Schnipper
Journal:  Am J Med       Date:  1986-03       Impact factor: 4.965

10.  Thymus-derived rosette-forming cells in various human disease states: cancer, lymphoma, bacterial and viral infections, and other diseases.

Authors:  J Wybran; H H Fudenberg
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.